Ahmed Elsharkawi, MD
Nephrology · Brunswick, GANPI 1861456378
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 58 manufacturers reported payments, led by Amgen at 46.5% of the total. Reporting peaked in 2023 at $8,967 and has fallen 83.6% since, to $1,474 in 2025. Among nephrology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 564 payments — averaging $33.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$9K
- CSL Behring$2K
- Mallinckrodt Hospital Products Inc.$1K
- AstraZeneca$1K
- Vifor Pharma, Inc.$571
- Novo Nordisk$489
- plus $5K from 52 others
Across 67 payments — averaging $11,283 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$237K
- AstraZeneca$193K
- Amgen$124K
- Vertex$103K
- Bayer$89K
- Alnylam Pharmaceuticals Inc.$10K
What the payments were for
- Speaking & faculty fees$6,00031%
- Travel & lodging$2,96616%
- Food & beverage$9,83451%
- Education$2501%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$7,567
How this compares
$19,110 in reported general payments places this provider in the 90th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 14 | $824,436 |
| JardianceEmpagliflozin | 383 | $366,378 |
| OzempicSemaglutide | 238 | $333,919 |
| MounjaroTirzepatide | 252 | $328,185 |
| KerendiaFinerenone | 278 | $249,712 |
| FarxigaDapagliflozin Propanediol | 233 | $197,301 |
| JanuviaSitagliptin Phosphate | 157 | $180,491 |
| EliquisApixaban | 178 | $179,734 |
| TrulicityDulaglutide | 103 | $128,924 |
| LinzessLinaclotide | 131 | $101,583 |
| LokelmaSodium Zirconium Cyclosilicate | 106 | $79,402 |
| CreonLipase/Protease/Amylase | 26 | $53,529 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $51,676 |
| VeltassaPatiromer Calcium Sorbitex | 37 | $47,818 |
| AuryxiaFerric Citrate | 19 | $44,486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $8,878 | $824,43614 claims |
| Lilly USA, LLCMounjaro, Trulicity | $284 | $457,109355 claims |
| Boehringer IngelheimJardiance, Tradjenta | $62 | $385,498415 claims |
| Novo NordiskOzempic | $489 | $333,919238 claims |
| AstraZenecaFarxiga, Lokelma, Symbicort | $1,017 | $282,882358 claims |
| BayerKerendia | $376 | $249,712278 claims |
| PfizerEliquis | $35 | $179,734178 claims |
| AbbVieLinzess, Creon | $358 | $155,112157 claims |
| Akebia Therapeutics IncAuryxia | $67 | $44,48619 claims |
| Fresenius USA Marketing, Inc.Velphoro | $323 | $28,51514 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $238 | $13,53911 claims |
| GSKBreo Ellipta | $267 | $9,24321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 nephrology providers in Georgia.
Other nephrology in Brunswick
- Colette Lee-LewisBrunswick$18K
- William GrubbBrunswick$11K
- Bryan KrullBrunswick$9K
- Sagar PanseMacon$542K
- Sheldon ShoreAtlanta$474K
- James TumlinLawrenceville$434K
- Salvatore ChillemiMarietta$287K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Don WilliamsonAugusta$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.